Document › Details

OncoMethylome Sciences B.V.. (2/12/10). "Press Release: Shareholder Notification". Liege.

Organisations Organisation OncoMethylome Sciences S.A.
  Today MDxHealth S.A. (Euronext: MDXH.BR)
  Group MDxHealth (Group)
  Organisation 2 APG Algemene Pensioen Groep N.V.
  Group ABP (Stichting Pensioenfonds) (Group)
Products Product molecular diagnostics
  Product 2 DNA methylation technology
Index term Index term OncoMethylome–Stichting Pensioenfonds: investment, 201002 existent APG Algemene Pensioen Groep NV holds 4.24% = 559,102 shares
Person Person Devine, Philip (MDxHealth/OncoMethylome 2003–201203 CFO + Co-founder LEFT 3/12)
     


OncoMethylome Sciences SA (Euronext Brussels: ONCOB, Euronext Amsterdam: ONCOA) reports that it received a transparency statement which shows that on February 3, 2010, APG Algemene Pensioen Groep NV held 559,102 shares (or 4.24%) of the total 13,185,614 outstanding OncoMethylome shares.

APG Algemene Pensioen Groep NV is the asset manager for the OncoMethylome shares previously declared as being held by Stichting Pensioenfonds ABP. APG Algemene Pensioen Groep NV is 98% owned by Stichting Pensioenfonds ABP.

For further details on the transparency notifications received by the company, reference is made to our website www.oncomethylome.com .

About OncoMethylome Sciences

OncoMethylome Sciences (Euronext Brussels: ONCOB; Euronext Amsterdam: ONCOA) is a molecular diagnostics company developing gene methylation tests to assist physicians in effectively detecting and treating cancer. Specifically, the company's tests are designed to help the physician (i) accurately detect cancer in early stages of cancer development, (ii) predict a patient's response to drug therapy, and (iii) predict the likelihood of cancer recurrence.

The company collaborates with leading international molecular oncology research centers, such as The Johns Hopkins University, and has a number of commercial and collaborative partnerships with LabCorp, Schering-Plough Corp., GlaxoSmithKline Biologicals , Millipore Corporation's BioScience Division, Merck KGaA and Qiagen. OncoMethylome's products are based on methylation technology invented by Johns Hopkins University (USA).

Established in January 2003, OncoMethylome has offices in Europe and in Durham, NC (USA).

For more information please contact:

Philip Devine
Tel. (+32) 4.364.20.70
ir@oncomethylome.com
www.oncomethylome.com

   
Record changed: 2015-08-07

Advertisement

[iito] Business Intelligence – The Elephants Are Coming 560x91px

More documents for MDxHealth (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px




» top